Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol

Euan A Sandilands, Sharon Cameron, Frances Paterson, Sam Donaldson, Lesley Briody, Jane Crowe, Julie Donnelly, Adrian Thompson, Neil R Johnston, Ivor Mackenzie, Neal Uren, Jane Goddard, David J Webb, Ian L Megson, Nicholas Bateman, Michael Eddleston, Euan A Sandilands, Sharon Cameron, Frances Paterson, Sam Donaldson, Lesley Briody, Jane Crowe, Julie Donnelly, Adrian Thompson, Neil R Johnston, Ivor Mackenzie, Neal Uren, Jane Goddard, David J Webb, Ian L Megson, Nicholas Bateman, Michael Eddleston

Abstract

Background: Contrast-induced nephropathy is a common complication of contrast administration in patients with chronic kidney disease and diabetes. Its pathophysiology is not well understood; similarly the role of intravenous or oral acetylcysteine is unclear. Randomized controlled trials to date have been conducted without detailed knowledge of the effect of acetylcysteine on renal function. We are conducting a detailed mechanistic study of acetylcysteine on normal and impaired kidneys, both with and without contrast. This information would guide the choice of dose, route, and appropriate outcome measure for future clinical trials in patients with chronic kidney disease.

Methods/design: We designed a 4-part study. We have set up randomised controlled cross-over studies to assess the effect of intravenous (50 mg/kg/hr for 2 hrs before contrast exposure, then 20 mg/kg/hr for 5 hrs) or oral acetylcysteine (1200 mg twice daily for 2 days, starting the day before contrast exposure) on renal function in normal and diseased kidneys, and normal kidneys exposed to contrast. We have also set up a parallel-group randomized controlled trial to assess the effect of intravenous or oral acetylcysteine on patients with chronic kidney disease stage III undergoing elective coronary angiography. The primary outcome is change in renal blood flow; secondary outcomes include change in glomerular filtration rate, tubular function, urinary proteins, and oxidative balance.

Discussion: Contrast-induced nephropathy represents a significant source of hospital morbidity and mortality. Over the last ten years, acetylcysteine has been administered prior to contrast to reduce the risk of contrast-induced nephropathy. Randomized controlled trials, however, have not reliably demonstrated renoprotection; a recent large randomized controlled trial assessing a dose of oral acetylcysteine selected without mechanistic insight did not reduce the incidence of contrast-induced nephropathy. Our study should reveal the mechanism of effect of acetylcysteine on renal function and identify an appropriate route for future dose response studies and in time randomized controlled trials.

Trial registration: Clinical Trials.gov: NCT00558142; EudraCT: 2006-003509-18.

Figures

Figure 1
Figure 1
4 way study design.
Figure 2
Figure 2
Schema of study drug administration. N, oral acetylcysteine.

References

    1. Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Intervent Radiol. 2005;28(Suppl 2):S3–11.
    1. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F. et al.Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98:5K–13K.
    1. Mehran R, Caixeta A. N-acetylcysteine in preventing contrast-induced nephropathy. To give, or not to give: that is the question. Rev Esp Cardiol. 2010;63:9–11.
    1. Stacul F. Reducing the risks for contrast-induced nephropathy. Cardiovasc Intervent Radiol. 2005;28(Suppl 2):S12–S18.
    1. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med. 1990;150:1237–1242. doi: 10.1001/archinte.1990.00390180067011.
    1. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol. 2004;183:1673–1689.
    1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930–936. doi: 10.1053/ajkd.2002.32766.
    1. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM. et al.The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542–1548. doi: 10.1016/S0735-1097(00)00917-7.
    1. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000;11:177–182.
    1. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114–2118. doi: 10.1016/S0735-1097(03)00487-X.
    1. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA. et al.Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98:59K–77K. doi: 10.1016/j.amjcard.2006.01.024.
    1. Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT) Circulation. 2011;124:1250–1259.
    1. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury. Circulation. 2011.
    1. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ. et al.Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328–2334. doi: 10.1001/jama.291.19.2328.
    1. Erdogan A, Davidson CJ. Recent clinical trials of iodixanol. Rev Cardiovasc Med. 2003;4(Suppl 5):S43–S50.
    1. Sandler CM. Contrast-agent-induced acute renal dysfunction--is iodixanol the answer? N Engl J Med. 2003;348:551–553. doi: 10.1056/NEJMe020183.
    1. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int. 2005;68:2256–2263. doi: 10.1111/j.1523-1755.2005.00684.x.
    1. Briguori C, Colombo A, Airoldi F, Morici N, Sangiorgi GM, Violante A. et al.Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int. 2005;68:2250–2255. doi: 10.1111/j.1523-1755.2005.00683.x.
    1. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491–499. doi: 10.1056/NEJMoa021833.
    1. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S. et al.Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515–1519. doi: 10.1016/j.amjcard.2004.03.008.
    1. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M. et al.A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–1399.
    1. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J. 2008;156:776–782. doi: 10.1016/j.ahj.2008.05.023.
    1. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med. 2006;166:161–166. doi: 10.1001/archinte.166.2.161.
    1. Eddleston M, Goddard J, Bateman N. N-acetylcysteine for contrast nephropathy: more clinical science is required. Arch Intern Med. 2006;166:1668–1669.
    1. Sunman W, Hughes AD, Sever PS. Anaphylactoid response to intravenous acetylcysteine. Lancet. 1992;339:1231–1232.
    1. Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate. Dos and don'ts for assessing kidney function. Postgrad Med. 2001;110:55–62.
    1. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407–410. doi: 10.1097/01.ASN.0000106780.14856.55.
    1. Jakobsen JA. Renal effects of iodixanol in healthy volunteers and patients with severe renal failure. Acta Radiol Suppl. 1995;399:191–195.
    1. Nelson L, Lewin N, Howland M, Hoffman R, Goldfrank L, Flomenbaum N. Goldfrank's Toxicologic Emergencies. 9. 2010.
    1. Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy. 2005;25:1095–1103. doi: 10.1592/phco.2005.25.8.1095.
    1. Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT. The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol. 1989;37:501–506. doi: 10.1007/BF00558131.
    1. Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) 2009;47:81–88. doi: 10.1080/15563650802665587.
    1. GE Healthcare. Visipaque 320: summary of product characteristics. Accessed 13 Jan 06.
    1. Sweetman SCE. Martindale: the extra pharmacopoeia. 34 2005.
    1. Nyman U, Almen T, Aspelin P, Hellstrom M, Kristiansson M, Sterner G. Contrast-medium-Induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in ml/min. Acta Radiol. 2005;46:830–842. doi: 10.1080/02841850500335051.
    1. Schnurr E, Lahme W, Kuppers H. Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol. 1980;13:26–29.
    1. Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am. 2005;89:457–473. doi: 10.1016/j.mcna.2004.11.009.
    1. Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H. et al.Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol. 2004;61:98–102.
    1. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2008;48:463–493. doi: 10.1146/annurev.pharmtox.48.113006.094615.
    1. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 1996;38:414–420. doi: 10.1136/gut.38.3.414.
    1. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J. et al.Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534–2543. doi: 10.1097/01.ASN.0000088027.54400.C6.
    1. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN. et al.Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology. 2006;105:485–491. doi: 10.1097/00000542-200609000-00011.
    1. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S. et al.Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57:772–779. doi: 10.1161/HYPERTENSIONAHA.110.167486.
    1. Fang LS, Sirota RA, Ebert TH, Lichtenstein NS. Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch Intern Med. 1980;140:531–533. doi: 10.1001/archinte.1980.00330160091033.
    1. Imai K, Toyo'oka T, Watanabe Y. A novel fluorogenic reagent for thiols: ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate. Anal Biochem. 1983;128:471–473. doi: 10.1016/0003-2697(83)90404-9.
    1. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3.
    1. Compton SJ, Jones CG. Mechanism of dye response and interference in the Bradford protein assay. Anal Biochem. 1985;151:369–374. doi: 10.1016/0003-2697(85)90190-3.
    1. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ. et al.Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation. 2004;109:1186–1193. doi: 10.1161/01.CIR.0000118499.69469.51.
    1. Tepel M, van der GM, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184. doi: 10.1056/NEJM200007203430304.
    1. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA. et al.A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007;5:32. doi: 10.1186/1741-7015-5-32.
    1. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284–294.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere